In May, the U.S. Supreme Court further clarified the patent enablement requirement in the case of Amgen Inc. v. Sanofi. The case revolved around Amgen’s patents claiming a broad class of antibodies that perform two cholesterol-lowering functions, yet the specifications of the patent only described 26 antibodies within that class.
This decision may appear to only impact life sciences technologies on the surface; however, it promises to transform how enablement is approached across various industries such as chemicals, artificial intelligence, and mechanical and electrical sectors, assert attorneys at Haynes Boone.
While the main focus of the case was on life science patents, its implications extend far beyond, signaling a broader change in the interpretation of patent enablement. Therefore, professionals working across different sectors should anticipate potential shifts in patent strategies and adjust their approaches accordingly.